.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Scientists recently reported promising results for Biologic Ventricular Assist Tissue (BioVAT) in the New England Journal of Medicine. Therefore, this technology represents a significant step forward in regenerative medicine for cardiac repair. In this open-label trial, clinicians treated patients with heart failure using allografts of engineered heart muscle. Moreover, the trial specifically targeted individuals with a reduced left ventricular ejection fraction (LVEF) of 35% or less. Consequently, the researchers observed meaningful improvements in both heart structure and patient symptoms.
The study highlights how BioVAT effectively remuscularizes damaged cardiac tissue. For instance, the target heart-wall thickness increased by an average of 4.5 mm after transplantation. Furthermore, the patients\' quality of life improved considerably, showing a 15.3-point increase in KCCQ-OSS scores. Although three patients died during the study, the investigators found no deaths directly related to the surgical procedure itself. Because of these findings, BioVAT may eventually offer a viable alternative to mechanical assist devices. Nevertheless, long-term safety data remains essential before widespread clinical adoption in India.
Additionally, the trial demonstrated a mean increase in LVEF of 4.7 percentage points among the treated group. This improvement suggests that the stem-cell-derived cardiomyocytes successfully integrated into the host heart. In fact, most patients who completed the follow-up showed sustainable results at the three-month mark. Thus, the safe maximal dose of 20 engineered-heart-muscle units appears both feasible and effective for terminal heart failure patients.
BioVAT is a tissue-engineered product composed of cardiomyocytes and stromal cells derived from induced pluripotent stem cells. It acts as a biological patch to repair and strengthen the failing heart.
It increases the thickness of the heart wall and improves the heart\'s pumping ability. Consequently, patients experience better physical function and fewer symptoms of heart failure.
Currently, BioVAT remains in the clinical trial phase. While results are promising, it is not yet available for routine clinical use outside of research settings.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Zimmermann WH et al. Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure. N Engl J Med. 2026 May 28. doi: 10.1056/NEJMoa2513525. PMID: 42202318.
ClinicalTrials.gov. BioVAT-HF: Safety and Efficacy of iPSC-derived Engineered Human Myocardium. NCT04396899.
FirstWord Pharma. BioVAT-HF Phase 1/2 Reveals First Evidence for Effective Heart Repair in Advanced Heart Failure. 2023 Nov 14.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A phase 1-2 study in NEJM shows BioVAT transplantation significantly increases heart wall thickness and ejection fraction in advanced heart failure patients...
last month
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
